Overview

Role of Parasympathetic Activity in Mild to Moderate Asthma With Irreversible or Fixed Airflow Obstruction

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
0
Participant gender:
All
Summary
In asthma, the major role of pathogenesis is chronic airway inflammation, bronchial hyperresponsiveness, and variable airflow obstruction, moreover, the autonomic nervous system also plays an important role in asthma, especially from the parasympathetic promoting bronchoconstriction and regulating airway inflammation and remodeling. Asthma with irreversible or fixed airflow obstruction (FAO) is a clinical phenotype. Although this condition frequently occurs in patients with severe asthma, there are pieces of evidence occurring in those with mild to moderate asthma. According to previous research, low lung function, FEV1 less than 60% predicted, is a strong independent predictor of subsequent asthma attacks and other asthma outcomes including asthma control and SABA use. In a recent study, the patients with mild to moderate asthma who received mild to medium dosed inhale corticosteroid plus long-acting beta-2 agonist with or without asthma control showed evidence of FAO with or without bronchodilator reversibility, therefore parasympathetic activity may be affected on FAO in those patients. The hypothesis of this study is a cholinergic mechanism may be a major role in FAO in mild to moderate asthma severity.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hat Yai Medical Education Center
Treatments:
Albuterol
Bromides
Ipratropium
Criteria
Inclusion Criteria:

- Asthmatic patients using low-dosed ICS/LABA or medium-dose ICS/LABA

- Post-bronchodilator (Salbutamol) FEV1/FVC ratio less than 0.75 or below the Lower
Limit of Normal (LLN) and Post-bronchodilator (Salbutamol) FEV1 predicted < 80% with
or without bronchodilator response

- History of smoking less than 10 pack-years

- Patients who able to do spirometry without contraindication

Exclusion Criteria:

- Contraindication for spirometry

- Chest x-ray suggested any chronic lung diseased

- Contraindication for anticholinergic drug

- History of asthma exacerbation within 12 weeks prior to visit 1

- History of taking LAMA within 6 months prior to visit 1